Rocket Pharmaceuticals, Inc.RCKTNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
27.42%
↑ 1847% above average
Average (39q)
1.41%
Historical baseline
Range
High:87.50%
Low:-107.55%
CAGR
-2.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 27.42% |
| Q2 2025 | -10.71% |
| Q1 2025 | 9.68% |
| Q4 2024 | 12.68% |
| Q3 2024 | 4.05% |
| Q2 2024 | -12.12% |
| Q1 2024 | -3.13% |
| Q4 2023 | 14.67% |
| Q3 2023 | 8.54% |
| Q2 2023 | -18.84% |
| Q1 2023 | 21.59% |
| Q4 2022 | -2.33% |
| Q3 2022 | -3.61% |
| Q2 2022 | -23.88% |
| Q1 2022 | 2.90% |
| Q4 2021 | 12.66% |
| Q3 2021 | -43.64% |
| Q2 2021 | 15.38% |
| Q1 2021 | 40.91% |
| Q4 2020 | -107.55% |
| Q3 2020 | -17.78% |
| Q2 2020 | 0.00% |
| Q1 2020 | -25.00% |
| Q4 2019 | 5.26% |
| Q3 2019 | 0.00% |
| Q2 2019 | 11.63% |
| Q1 2019 | 29.51% |
| Q4 2018 | -52.50% |
| Q3 2018 | 0.00% |
| Q2 2018 | 4.76% |
| Q1 2018 | 41.67% |
| Q4 2017 | 33.94% |
| Q3 2017 | -12.37% |
| Q2 2017 | 38.22% |
| Q1 2017 | 18.23% |
| Q4 2016 | -16.36% |
| Q3 2016 | -26.92% |
| Q2 2016 | 14.47% |
| Q1 2016 | -22.58% |
| Q4 2015 | 87.50% |